Breaking News

Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.

Gene expression data revealed two groups of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinomas corresponding to distinct survival outcomes.

Researchers from the PROREPAIR-B study reported that men with germline BRCA2 mutations and prostate cancer had shorter cause-specific survival.

In a small study, melanoma patients with BRAF V600K mutations responded better to immunotherapy while those with V600E mutations had a better response to targeted therapy.

The firm plans to offer more than 13 million shares of its common stock at $.225 per share. The offering will close on or about Jan. 14.

The company plans to focus on increasing its NIPT reimbursement as well as on pharmaceutical deals for its oncology test and launching a kidney transplantation test.

Arbor Biosciences' portfolio includes custom DNA microarrays and oligonucleotide libraries, as well as a line of targeted sequencing panels.

Unveiled in September, the HuBMAP program is an open, global framework supporting efforts to build a map of cells within the adult human body.

After a successful pilot that recruited 1,000 patients, NorthShore will now engage 10,000 people to receive Color's genomic testing in their primary care.

In an effort to lift patient access barriers, the company is launching a model whereby consumers will be able to initiate test orders online.

An array-based analysis involving more than two dozen patients led to a miRNA signature associated with overall survival in primary central nervous system lymphoma.

The subsidiary of Canon USA shut down as of Dec. 31 and terminated a distribution agreement with Dutch PCR company Molecular Biology Systems.

The company is also looking to expand the use of its FDA-approved ClonoSeq assay, which has US FDA approval for MRD detection in acute lymphocytic leukemia and multiple myeloma.

A busy second day of the JP Morgan conference saw Thermo Fisher's Marc Casper discuss the firm's R&D focus and Exact Sciences' Kevin Conroy discuss plans for Cologuard sales growth.

The molecular test detects and differentiates Bordetella pertussis and Bordetella parapertussis from fresh and frozen nasopharyngeal swab samples.

The firm said it will spend the funds on new marketing efforts and on increasing its sales team to handle growing customer demand.

GreenLight Biosciences is using a proprietary cell-free RNA production technology to develop RNA-based products for the agricultural market.

In a colon cancer model, researchers saw transcriptional changes and population expansions in some checkpoint receptor-negative tumor-infiltrating T cells.

At JP Morgan, Qiagen CEO Peer Schatz discussed a new digital PCR system and handheld reader for TB testing; Qiagen's acquisition of N-of-One; and its new sample prep system.

Investigators analyzed the inactivation of tumor suppressor genes and its transcriptional consequences in thousands of tumors from 33 cancer types or subtypes.

The company said it expects revenues from its ePlex analyzers to go up approximately 110 percent year over year for Q4.

The firm's fourth quarter preliminary revenues increased by 11 percent to $865 million year over year, while full-year revenues jumped by 21 percent to $3.3 billion.

Cell Guidance Systems will use Expedeon's Lightning-Link Rapid Biotin reagent kit in the development of its TRIFic exosome immunoassay technology.

Among the firms presenting, 10x noted that it doubled its revenue growth in 2018, and Myriad discussed the impact that new tests are having on its growth.

The tests are designed to detect genetic variations including SNPs, insertion-deletions, copy number variations, and variations in segmental duplications.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.